Brief: Oncolytics Biotech Announces Publication Of Pelareorep's Clinical Benefit
02/04/2020 12:09
April 2 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* ONCOLYTICS BIOTECH® ANNOUNCES PUBLICATION OF PELAREOREP'S
CLINICAL BENEFIT AGAINST KRAS MUTATED COLORECTAL CANCER
Source text for Eikon: ID:nPn6p32b8a
Further company coverage: ONC.TO
((Reuters Messaging: Reuters.Briefs@thomsonreuters.com))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Files For Mixed Shelf Offering Of Up To $150 Million
Brief: Oncolytics Biotech® Announces Voluntary Delisting From The Toronto Stock Exchange
Advisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
Brief: Oncolytics Biotech® Appoints Former Ambrx Executive As Chief Business Officer
Brief: Oncolytics Biotech Appoints Former Ambrx Executive As Chief Business Officer